UY39658A - Formulación y métodos de gliburida de baja absorción - Google Patents
Formulación y métodos de gliburida de baja absorciónInfo
- Publication number
- UY39658A UY39658A UY0001039658A UY39658A UY39658A UY 39658 A UY39658 A UY 39658A UY 0001039658 A UY0001039658 A UY 0001039658A UY 39658 A UY39658 A UY 39658A UY 39658 A UY39658 A UY 39658A
- Authority
- UY
- Uruguay
- Prior art keywords
- methods
- glyburide
- low absorption
- delivering
- solution
- Prior art date
Links
- 229960004580 glibenclamide Drugs 0.000 title abstract 3
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000010521 absorption reaction Methods 0.000 title 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012535 impurity Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 238000001179 sorption measurement Methods 0.000 abstract 1
- 239000002699 waste material Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
- C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
- C07C311/58—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
- C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
- C07C311/59—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Métodos y formulaciones para minimizar o evitar la sorción de gliburida en las superficies de los tubos de suministro, filtros, bolsas y otros recipientes y materiales, almacenando y suministrando así un producto más estable, suministrando una dosis predecible y precisa de la gliburida, al tiempo que minimiza las impurezas, evita el desperdicio de medicamentos, reduce los costos y reduce significativamente la cantidad de solución de dosificación (generalmente solución salina o solución de Ringer) que se debe infundir al paciente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163156533P | 2021-03-04 | 2021-03-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY39658A true UY39658A (es) | 2022-09-30 |
Family
ID=80930067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001039658A UY39658A (es) | 2021-03-04 | 2022-03-04 | Formulación y métodos de gliburida de baja absorción |
Country Status (11)
Country | Link |
---|---|
US (2) | US20220280537A1 (es) |
EP (1) | EP4301337A2 (es) |
JP (1) | JP2024512310A (es) |
KR (1) | KR20230165778A (es) |
CN (1) | CN117320727A (es) |
AR (1) | AR125033A1 (es) |
CA (1) | CA3210407A1 (es) |
MX (1) | MX2023010313A (es) |
TW (1) | TW202302117A (es) |
UY (1) | UY39658A (es) |
WO (1) | WO2022187567A2 (es) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1269578B (it) * | 1994-04-22 | 1997-04-08 | Chiesi Farma Spa | Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base. |
US20030175349A1 (en) * | 2001-01-30 | 2003-09-18 | Council Of Scientific And Industrial Research | Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient |
JP2009513294A (ja) | 2005-10-30 | 2009-04-02 | メディモップ・メディカル・プロジェクツ・リミテッド | ニードルレス添加剤制御バルブ |
DE212014000169U1 (de) | 2013-08-07 | 2016-03-14 | Medimop Medical Projects Ltd. | Flüssigkeitstransfervorrichtungen zur Verwendung mit Infusionsflüssigkeitsbehältern |
CN108210501B (zh) * | 2016-12-14 | 2019-03-08 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种磺酰脲类药物的注射用药物组合物及其制备方法 |
-
2022
- 2022-03-04 TW TW111107963A patent/TW202302117A/zh unknown
- 2022-03-04 US US17/686,538 patent/US20220280537A1/en active Pending
- 2022-03-04 MX MX2023010313A patent/MX2023010313A/es unknown
- 2022-03-04 CA CA3210407A patent/CA3210407A1/en active Pending
- 2022-03-04 CN CN202280032626.3A patent/CN117320727A/zh active Pending
- 2022-03-04 EP EP22712158.9A patent/EP4301337A2/en active Pending
- 2022-03-04 KR KR1020237033801A patent/KR20230165778A/ko unknown
- 2022-03-04 UY UY0001039658A patent/UY39658A/es unknown
- 2022-03-04 AR ARP220100498A patent/AR125033A1/es unknown
- 2022-03-04 WO PCT/US2022/018821 patent/WO2022187567A2/en active Application Filing
- 2022-03-04 JP JP2023553299A patent/JP2024512310A/ja active Pending
-
2024
- 2024-04-15 US US18/635,765 patent/US20240285654A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20230165778A (ko) | 2023-12-05 |
JP2024512310A (ja) | 2024-03-19 |
WO2022187567A3 (en) | 2022-10-20 |
CN117320727A (zh) | 2023-12-29 |
CA3210407A1 (en) | 2022-09-09 |
AR125033A1 (es) | 2023-05-31 |
WO2022187567A2 (en) | 2022-09-09 |
US20220280537A1 (en) | 2022-09-08 |
EP4301337A2 (en) | 2024-01-10 |
TW202302117A (zh) | 2023-01-16 |
US20240285654A1 (en) | 2024-08-29 |
MX2023010313A (es) | 2023-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9207200A (es) | Formulacion farmaceutica en aerosol, bote para suministrar dicha formulacion e inhalador de dosis dosificada que comprende dicho bote. | |
CO5031245A1 (es) | Inhaladores de dosis regulada a presion y formulaciones farmaceuticas de aerosol | |
CO5680461A2 (es) | Productos farmaceuticos que comprenden bisfosfonatos | |
AR058838A1 (es) | Metodo para tratar el dano articular | |
NO20010091L (no) | Medisinsk leveringsinnretning og en patronsammenstilling for bruk med denne | |
JP2007502684A5 (es) | ||
ES2824787T3 (es) | Soluciones embaladas de alta estabilidad de hormona tiroidea T4 | |
RU2740910C2 (ru) | Офтальмологическая композиция, содержащая повидон-иод | |
CO2021002433A2 (es) | Un método de obtención de la forma de dosis líquida del medicamento edaravone, que es estable durante el almacenamiento, transporte y de uso conveniente | |
JP2023002627A (ja) | 眼科組成物 | |
MX2018000258A (es) | Dispositivo de suministro de un solo uso. | |
UY39658A (es) | Formulación y métodos de gliburida de baja absorción | |
RU2012154628A (ru) | Фармацевтическая композиция ибупрофена для инъекции | |
CN101674803A (zh) | 浓艾司洛尔 | |
RU2015119223A (ru) | Система дозированного распределения | |
WO2014120293A1 (en) | Ophthalmic formulations | |
MX2015004962A (es) | Composicion inyectable estable que contiene diclofenaco y tiocolchicosido. | |
JP7153999B2 (ja) | 水性組成物 | |
JP2014009022A (ja) | 滴下式エアゾール製品 | |
CO2018009584A2 (es) | Composición anestésica tópica | |
RU2002129356A (ru) | Комбинация лекарственных средств для лечения головной боли, содержащая нестероидное противовоспалительное лекарственное средство | |
JP2017197527A (ja) | 眼科組成物 | |
US20160144033A1 (en) | Concentrated acetaminophen solution | |
WO2017183714A1 (ja) | 眼科組成物 | |
AR083893A1 (es) | Uso de una composicion farmaceutica que comprende (s) (3-(1-(1h-imidazol-4-il)etil)-2-metilfenil)metanol para preparar un medicamento topico de utilidad en la reduccion de la presion intraocular y articulo de manufactura correspondiente |